Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
48.93
Dollar change
+0.63
Percentage change
1.30
%
IndexS&P 500 P/E12.68 EPS (ttm)3.86 Insider Own0.08% Shs Outstand2.03B Perf Week1.35%
Market Cap99.17B Forward P/E6.95 EPS next Y7.04 Insider Trans0.84% Shs Float2.03B Perf Month-5.69%
Income8.03B PEG- EPS next Q-4.42 Inst Own78.18% Short Float1.73% Perf Quarter-2.35%
Sales45.01B P/S2.20 EPS this Y-91.12% Inst Trans-0.74% Short Ratio2.26 Perf Half Y-13.93%
Book/sh14.56 P/B3.36 EPS next Y955.42% ROA8.36% Short Interest35.12M Perf Year-29.96%
Cash/sh6.09 P/C8.04 EPS next 5Y-4.17% ROE26.53% 52W Range47.58 - 70.93 Perf YTD-4.64%
Dividend Est.2.44 (4.98%) P/FCF7.84 EPS past 5Y5.14% ROI11.87% 52W High-31.02% Beta0.42
Dividend TTM2.34 (4.78%) Quick Ratio1.31 Sales past 5Y16.92% Gross Margin56.34% 52W Low2.84% ATR (14)0.92
Dividend Ex-DateApr 04, 2024 Current Ratio1.43 EPS Y/Y TTM30.29% Oper. Margin18.78% RSI (14)39.16 Volatility1.63% 1.70%
Employees34100 Debt/Eq1.41 Sales Y/Y TTM-2.50% Profit Margin17.83% Recom2.67 Target Price55.70
Option/ShortYes / Yes LT Debt/Eq1.30 EPS Q/Q-8.96% Payout59.82% Rel Volume0.65 Prev Close48.30
Sales Surprise2.54% EPS Surprise9.42% Sales Q/Q0.62% EarningsApr 25 BMO Avg Volume15.57M Price48.93
SMA20-4.03% SMA50-4.27% SMA200-10.34% Trades Volume10,303,913 Change1.30%
Date Action Analyst Rating Change Price Target Change
Mar-11-24Downgrade Societe Generale Buy → Hold
Feb-06-24Downgrade Redburn Atlantic Buy → Neutral $77 → $54
Jan-03-24Downgrade BofA Securities Buy → Neutral $68 → $60
Nov-15-23Downgrade Cantor Fitzgerald Overweight → Neutral $68 → $55
Nov-09-23Initiated Deutsche Bank Hold $55
Nov-02-23Downgrade Daiwa Securities Outperform → Neutral $68 → $54
Oct-27-23Upgrade HSBC Securities Reduce → Hold $55 → $53
Oct-27-23Downgrade William Blair Outperform → Mkt Perform
Oct-27-23Downgrade BMO Capital Markets Outperform → Market Perform $60
Oct-20-23Resumed UBS Neutral $70 → $60
Apr-11-24 09:10AM
Apr-08-24 11:30AM
07:00AM
Apr-06-24 08:47PM
01:15PM
01:15PM Loading…
01:15PM
Apr-05-24 09:05AM
Apr-02-24 08:08PM
02:30PM
Apr-01-24 07:30AM
Mar-31-24 08:35AM
Mar-29-24 12:09PM
09:45AM
Mar-28-24 04:05PM
04:01PM
07:30AM Loading…
07:30AM
Mar-26-24 07:19AM
06:59AM
Mar-25-24 08:21AM
08:00AM
Mar-21-24 03:00PM
Mar-20-24 04:45PM
08:58AM
06:59AM
Mar-19-24 06:59AM
Mar-18-24 07:32PM
09:52AM
08:44AM
08:00AM
Mar-15-24 06:27PM
12:17PM Loading…
12:17PM
Mar-14-24 09:35PM
10:56AM
Mar-13-24 09:03AM
Mar-12-24 08:30AM
Mar-11-24 04:16PM
07:56AM
Mar-07-24 02:23PM
09:10AM
Mar-06-24 04:17PM
Mar-05-24 10:38AM
09:06AM
02:56AM
Mar-04-24 09:06AM
Mar-01-24 04:16PM
Feb-29-24 06:59AM
Feb-28-24 07:34AM
Feb-26-24 04:16PM
08:35AM
Feb-25-24 05:46PM
Feb-24-24 02:31PM
Feb-23-24 06:59AM
06:59AM
Feb-22-24 07:00AM
Feb-20-24 06:59AM
06:30AM
Feb-14-24 07:57PM
04:16PM
08:30AM
06:59AM
Feb-12-24 06:59AM
Feb-07-24 08:55AM
06:59AM
Feb-05-24 09:20AM
06:59AM
Feb-03-24 08:49AM
Feb-02-24 11:37AM
10:58AM
07:26AM
06:59AM
Feb-01-24 05:23PM
09:29AM
05:30AM
Jan-30-24 09:15AM
06:59AM
Jan-27-24 10:00AM
Jan-26-24 07:13AM
Jan-23-24 08:30AM
Jan-22-24 05:05PM
05:00PM
Jan-20-24 10:00AM
Jan-18-24 02:41PM
Jan-17-24 06:59AM
Jan-10-24 04:15PM
Jan-08-24 08:37PM
Jan-02-24 06:59AM
Dec-27-23 07:04PM
12:13PM
09:39AM
Dec-26-23 03:31PM
02:34PM
12:33PM
11:47AM
11:42AM
09:23AM
09:00AM
07:13AM
Dec-22-23 03:44PM
01:26PM
09:46AM
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shanahan KarinEVP, Glob. Prod. Dev. & SupplyApr 01 '24Option Exercise0.003,30606,532Apr 02 06:45 PM
Lenkowsky AdamEVP, Chief Commercial OfficerMar 10 '24Option Exercise0.0015,016013,859Mar 12 09:54 PM
LEUNG SANDRAEVP, General CounselMar 10 '24Option Exercise0.0046,7840371,312Mar 12 09:43 PM
Plenge Robert MEVP, Chief Research OfficerMar 10 '24Option Exercise0.009,143015,182Mar 12 09:21 PM
Poole Ahn AmandaEVP, Chief Human ResourcesMar 10 '24Option Exercise0.005,45804,841Mar 12 09:11 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Mar 10 '24Option Exercise0.0038,388080,256Mar 12 08:40 PM
Holzer Phil MSVP and ControllerMar 10 '24Option Exercise0.005,520014,916Mar 12 08:31 PM
Hoch LynellePresident, Cell Therapy Org.Mar 10 '24Option Exercise0.004,35103,781Mar 12 08:01 PM
Gallman CariEVP, Corporate AffairsMar 10 '24Option Exercise0.002,76102,655Mar 12 08:00 PM
BOERNER CHRISTOPHER S.Chief Executive OfficerMar 10 '24Option Exercise0.0054,6380129,769Mar 12 07:58 PM
Elkins David VEVP, Chief Financial OfficerMar 10 '24Option Exercise0.0064,3260225,111Mar 12 05:43 PM
Caforio GiovanniExecutive Chair of the BoardMar 10 '24Option Exercise0.00190,1300529,662Mar 12 05:42 PM
Meyers Gregory ScottEVP, Chief Digital & Tech Off.Feb 01 '24Option Exercise0.002,54306,040Feb 05 07:10 PM
BOERNER CHRISTOPHER S.Chief Executive OfficerDec 05 '23Buy49.782,00099,56082,672Dec 07 06:06 PM
Plenge Robert MEVP, Chief Research OfficerDec 02 '23Option Exercise0.0061607,200Dec 05 06:23 PM
Elkins David VEVP, Chief Financial OfficerDec 02 '23Option Exercise0.008,7920172,342Dec 05 06:22 PM
BOERNER CHRISTOPHER S.Chief Executive OfficerDec 02 '23Option Exercise0.002,638082,022Dec 05 06:21 PM
BOERNER CHRISTOPHER S.Chief Executive OfficerNov 28 '23Buy48.863,071150,04979,384Nov 30 06:32 PM
Samuels Theodore R. IIDirectorNov 20 '23Buy49.818,500423,38535,500Nov 21 07:01 PM
Powell AnnEVP, Chief Human ResourcesAug 24 '23Sale61.2517,9861,101,64227,868Aug 28 05:28 PM
Plenge Robert MEVP, Chief Research OfficerAug 03 '23Sale61.1473244,7546,584Aug 07 05:24 PM
Weese MichelleEVP, Corporate AffairsJul 01 '23Option Exercise0.001,88504,135Jul 05 05:26 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Jul 01 '23Option Exercise0.009,357052,032Jul 05 05:23 PM
Lenkowsky AdamEVP, Chief Commercial OfficerJun 03 '23Option Exercise0.001,07701,077Jun 06 07:39 PM
VESSEY RUPERTEVP & President, ResearchMay 03 '23Sale67.0650,3853,378,81847,751May 04 05:51 PM
Greenlees SharonSVP & ControllerMay 02 '23Option Exercise0.001,0170728May 03 07:36 PM